Akari Therapeutics Secures Key European Patent For Its Novel RNA Splicing Modulator ADC Payload, Strengthening Global IP Estate For All Major Global Markets

Akari’s lead program, AKTX-101, a TROP2-targeting ADC powered by its proprietary PH1 payload, is currently in IND-enabling ...
Labroots

Key Considerations for an Effective CMC Development Strategy in ADC Projects

Antibody-drug conjugates (ADCs) are transforming oncology with their ability to deliver potent cytotoxic agents directly to ...
Yahoo Finance

Defence Therapeutics to Build ADC Drug Delivery Powerhouse Using Its Proprietary Accum Technology

Montreal, Quebec--(Newsfile Corp. - November 19, 2025) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTCQB: DTCFF) ("Defence" or the "Company"), a leading ...
Hosted on MSN

GSK targets Syndivia’s prostate cancer ADC in £268m buy

GSK has acquired the rights to Syndivia’s preclinical antibody drug conjugate (ADC), which is in development for prostate cancer treatment, fuelling the ongoing industry buzz for the promising ...
C&EN

AstraZeneca to build $1.5 billion ADC facility in Singapore

The UK pharma giant AstraZeneca will invest $1.5 billion to build its first end-to-end antibody-drug conjugate (ADC) manufacturing facility in Singapore. The plant will be designed to manufacture all ...
News Medical

Expanding new trends and technologies in ADC therapeutics

Antibody-drug conjugates (ADCs) are a growing class of biotherapeutics that have transformed targeted therapy, especially in oncology. By making use of monoclonal antibodies’ specificity to deliver ...